東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"History of Japan." ]

切換: 標籤 | MARC模式 | ISBD

Drug discovery in Japan = investigat...

Nagaoka, Sadao.

FindBook

Google Book

Amazon

博客來

Drug discovery in Japan = investigating the sources of innovation /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Drug discovery in Japan/ edited by Sadao Nagaoka.
其他題名:	investigating the sources of innovation /
其他作者:	Nagaoka, Sadao.
出版者:	Singapore :Springer Singapore : : 2019.,
面頁冊數:	xv, 333 p. :ill. (some col.), digital ;24 cm.
內容註:	Foreword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications.
Contained By:	Springer eBooks
標題:	Drug development - Japan. -
電子資源:	https://doi.org/10.1007/978-981-13-8906-1
ISBN:	9789811389061

Drug discovery in Japan = investigating the sources of innovation /
Drug discovery in Japaninvestigating the sources of innovation /[electronic resource] :edited by Sadao Nagaoka. - Singapore :Springer Singapore :2019. - xv, 333 p. :ill. (some col.), digital ;24 cm.

Foreword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications.

This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices.

ISBN: 9789811389061

Standard No.: 10.1007/978-981-13-8906-1doiSubjects--Topical Terms:

873207
Drug development
--Japan.

LC Class. No.: RM301.25 / .D784 2019

Dewey Class. No.: 615.19

Drug discovery in Japan = investigating the sources of innovation /
LDR:03171nmm a2200325 a 4500 001 2218871
003 DE-He213
005 20200120134850.0
006 m d
007 cr nn 008maaau
008 201126s2019 si s 0 eng d
020 $a 9789811389061 $q (electronic bk.)
020 $a 9789811389054 $q (paper)
024 7 $a 10.1007/978-981-13-8906-1 $2 doi
035 $a 978-981-13-8906-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25 $b .D784 2019
072 7 $a KJMV6 $2 bicssc
072 7 $a SCI000000 $2 bisacsh
072 7 $a KJMV6 $2 thema
082 0 4 $a 615.19 $2 23
090 $a RM301.25 $b .D794 2019
245 0 0 $a Drug discovery in Japan $h [electronic resource] : $b investigating the sources of innovation / $c edited by Sadao Nagaoka.
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2019.
300 $a xv, 333 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Foreword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications.
520 $a This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices.
650 0 $a Drug development $z Japan. $3 873207
650 1 4 $a R & D/Technology Policy. $3 895529
650 2 4 $a Innovation/Technology Management. $3 1565353
650 2 4 $a History of Japan. $3 2181997
700 1 $a Nagaoka, Sadao. $3 3453673
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u https://doi.org/10.1007/978-981-13-8906-1
950 $a Economics and Finance (Springer-41170)